Chimerix Ready To Take CMV Candidate CMX001 Into Phase III
This article was originally published in The Pink Sheet Daily
The New England Journal of Medicine rarely highlights Phase II results, but Chimerix’s mid-stage study shows that its CMX001 could be a game-changing therapy for helping treat and prevent harmful infections that occur in patients after transplants.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.